Active substance
Results for the substance tofacitinib
4 results
About this active substance
Tofacitinib is a Janus kinase (JAK) inhibitor used in the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by inhibiting the JAK-STAT signaling pathway, reducing inflammation and the abnormal immune response associated with these conditions.
Tofacitinib is administered orally, usually twice daily, with the dose adjusted based on the patient's response and tolerability. It is often used as a second-line therapy for patients who do not respond adequately to conventional treatments.
Common side effects include upper respiratory tract infections, nausea, headache, and increased cholesterol levels. In rare cases, severe adverse reactions such as serious infections, thrombosis, or liver function impairment may occur. Regular monitoring of clinical parameters is essential during treatment.
Tofacitinib is an innovative therapeutic option for patients with chronic inflammatory diseases, contributing to symptom relief and improved quality of life.
Tofacitinib is administered orally, usually twice daily, with the dose adjusted based on the patient's response and tolerability. It is often used as a second-line therapy for patients who do not respond adequately to conventional treatments.
Common side effects include upper respiratory tract infections, nausea, headache, and increased cholesterol levels. In rare cases, severe adverse reactions such as serious infections, thrombosis, or liver function impairment may occur. Regular monitoring of clinical parameters is essential during treatment.
Tofacitinib is an innovative therapeutic option for patients with chronic inflammatory diseases, contributing to symptom relief and improved quality of life.
-
-
XELJANZ 11mg prolonged-release tablets PFIZER ORIGINAL MEDICINE
-
XELJANZ 1mg/ml oral solution PFIZER ORIGINAL MEDICINE
-
XELJANZ 5mg film-coated tablets PFIZER ORIGINAL MEDICINE